Lexaria Bioscience Corp. (LEXX) Stock Forecast
LEXX analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $82.50 average of analyst targets
- Upside to target
- +2,784.6% from the latest close
- Next earnings
- November 25, 2026 EPS estimate $-0.90
- 52-week range
- $2.77 – $20.10
LEXX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LEXX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$4.05 | −$4.05 | −$4.05 | −$9.90 | +59.1% | 1 |
| Next fiscal year (FY2027) | −$4.65 | −$4.65 | −$4.65 | −$4.05 | −14.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LEXX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Nov '26) | $0 | $0 | $0 | — | — |
| Current fiscal year (FY2026) | $20,000 | $20,000 | $20,000 | −97.2% | 1 |
| Next fiscal year (FY2027) | $1.4M | $1.4M | $1.4M | +6,915.0% | 1 |
LEXX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LEXX revenue: reported and forecast
LEXX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (FY2026) | −$3.90 | −$3.90 | −$3.90 | −$3.90 | −$4.05 | +3.8% | 0 up · 1 down |
| Next fiscal year (FY2027) | −$4.65 | −$4.65 | −$4.65 | −$4.65 | −$4.65 | 0.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LEXX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LEXX beat in 6 of 12.
What analysts expect from LEXX
The average price target is $82.50, 2,784.6% above the latest close of $2.86. Analysts expect earnings of −$4.05 per share for FY2026, +59.1% from a year earlier. For FY2027 the average estimate is −$4.65 per share on revenue of $1.4 million. Lexaria Bioscience beat the EPS estimate in 6 of the last 12 quarters.
Related: LEXX income statement, LEXX key metrics, LEXX chart. See the LEXX stock overview for the latest quote and news.
LEXX forecast FAQ
What is Lexaria Bioscience's price target?
The average analyst price target for Lexaria Bioscience is $82.50, 2,784.6% above the latest close of $2.86.
What is Lexaria Bioscience's EPS forecast?
Analysts forecast −$4.05 per share for FY2026 (range −$4.05 to −$4.05); for FY2027 the estimate is −$4.65.
What is Lexaria Bioscience's revenue forecast?
The average revenue estimate for FY2026 is $0.0 million, growth of −97.2%; for FY2027 it is $1.4 million.
When does Lexaria Bioscience report earnings?
Lexaria Bioscience is expected to report results for the quarter ending August 31, 2026 on November 25, 2026; the EPS estimate is $-0.90.
Does Lexaria Bioscience usually beat earnings estimates?
Lexaria Bioscience reported EPS at or above the analyst estimate in 6 of the last 12 quarters.